Get the Stockscreener App
1.96
2.62%
0.05
X T L Biopharmaceuticals Ltd Adr stock is traded at $1.96, with a volume of 1,530.
It is up +2.62% in the last 24 hours and down -17.99% over the past month.
XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
See More
Previous Close:
$1.91
Open:
$1.94
24h Volume:
1,530
Relative Volume:
0.13
Market Cap:
$4.82M
Revenue:
$453.80K
Net Income/Loss:
$-1.03M
P/E Ratio:
-2.7283
EPS:
-0.7184
Net Cash Flow:
$-717.00K
1W Performance:
-1.01%
1M Performance:
-17.99%
6M Performance:
-20.97%
1Y Performance:
-62.88%
1-Day Range:
$1.94
$2.0127
1-Week Range:
$1.86
$2.0127
52-Week Range:
$1.86
$14.56
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Company Profile
Name
X T L Biopharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare XTLB vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XTLB
X T L Biopharmaceuticals Ltd Adr
|
1.96 | 4.82M | 453.80K | -1.03M | -717.00K | -0.7184 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-15 | Initiated | H.C. Wainwright | Buy |
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Latest News
XTL Biopharmaceuticals (XTLB) Edges Higher as Shares Test $2.29 ResistanceRVOL Spike - https://www.dars.gov.et/
XTL Biopharmaceuticals (XTLB) Edges Higher as Shares Test $2.29 ResistanceIsland Reversal - siam.in
XTLB Stock Edges Higher: XTL Biopharmaceuticals ADR Ticks Up 0.46% to $2.17KAMA Signal - siam.in
XTL Biopharmaceuticals (XTLB) Trades Flat at $2.56, Sitting Midway Between Support and ResistanceFactor Rotation - siam.in
XTL Biopharmaceuticals (XTLB) Trades Flat at $2.56, Sitting Midway Between Support and ResistanceLiquidity Sweep - dars.gov.et
XTL Biopharmaceuticals (XTLB) Trades Flat at $2.56, Sitting Midway Between Support and ResistanceFibonacci Entry Signals - dars.gov.et
XTL Biopharmaceuticals (XTLB) Advances 4.2% to $2.48 as Clinical-Stage Biotech Draws Fresh Buying Interest - careplusvn.com
XTL Biopharmaceuticals (XTLB) Advances 4.2% to $2.48 as Clinical-Stage Biotech Draws Fresh Buying InterestBeta Neutral Pair - dars.gov.et
XTL Biopharmaceuticals (XTLB) Advances 4.2% to $2.48 as Clinical-Stage Biotech Draws Fresh Buying InterestIV Spike - www.dars.gov.et
XTL Biopharmaceuticals (XTLB) Advances 4.2% to $2.48 as Clinical-Stage Biotech Draws Fresh Buying InterestIV Crush Alert - https://www.dars.gov.et/
XCharge Announces Plan to Implement ADS Ratio Change - Yahoo Finance
XTL Biopharmaceuticals (XTLB) Slides 2.38% as Shares Approach Key Support at $2.73Max Pain Level - dars.gov.et
XTL Biopharmaceuticals (XTLB) Slips 7.67% to $2.65, Nears Key Support at $2.52ATR Stop - dars.gov.et
XTL Biopharmaceuticals Faces Derivative Action Bid Over Failed Social Proxy Acquisition - TipRanks
XTL Biopharmaceuticals Ltd. Sponsored ADR Revenue Breakdown – FWB:HHB0 - TradingView
XTL Biopharmaceuticals Regains Nasdaq Compliance and Enters One-Year Monitoring Period - The Globe and Mail
XTL Biopharmaceuticals Regains Nasdaq Compliance and Enters One-Year Monitoring Period - TipRanks
Enterprise value to EBITDA forward of XTL Biopharmaceuticals Ltd. Sponsored ADR – LSX:A41X7J - TradingView
XTL Biopharmaceuticals Completes Psyga Bio Acquisition, Refocuses on Psychedelic Medicine - TipRanks
XTL buys Psyga Bio, taking control of 83.4% of shares - Stock Titan
XTL Biopharmaceuticals Shareholders Approve Psyga Bio Acquisition and Major Capital Increase - TipRanks
Wondering what's happening in today's after-hours session? - ChartMill
XTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026 - TipRanks
XTLB Stock Price, Quote & Chart - ChartMill
XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis $XTLB - MarketBeat
XTLB - Finviz
Wondering what's happening in today's after-hours session? - ChartMill
XTL Biopharmaceuticals Faces Added Nasdaq Delisting Risk Over Late 2025 Annual Report - TipRanks
XTL Biopharmaceuticals faces additional Nasdaq delisting risk - Investing.com
Eastern International Ltd. expands board, appoints two new directors - Investing.com
XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise - The Globe and Mail
XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise - TipRanks
SMX increases authorized shares for incentive plan and grants restricted stock units - Investing.com
XTL Biopharmaceuticals Wins Conditional Nasdaq Listing Reprieve Tied to Psyga Bio Deal - TipRanks
XTL Biopharmaceuticals Delays 20-F Amid Subsidiary Liquidation - TipRanks
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.57% - Investing.com
XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline - TipRanks
XTL Biopharmaceuticals to acquire Psyga Bio for 40% stake - Investing.com
Double BottomStock ScreenerCharts - Finviz
Top GainersStock ScreenerSnapshot - Finviz
XTL Biopharmaceuticals Ltd ADR Each REPR 40 share price | XTLB - Hargreaves Lansdown
Debt to assets ratio of XTL Biopharmaceuticals Ltd. Sponsored ADR – GETTEX:HHB0 - TradingView
Total assets of XTL Biopharmaceuticals Ltd. Sponsored ADR – SWB:HHB0 - TradingView
Return on invested capital % of XTL Biopharmaceuticals Ltd. Sponsored ADR – SWB:HHB0 - TradingView
Free cash flow per share of XTL Biopharmaceuticals Ltd. Sponsored ADR – GETTEX:HHB0 - TradingView
Tangible book value per share of XTL Biopharmaceuticals Ltd. Sponsored ADR – SWB:HHB0 - TradingView
XTL Biopharmaceuticals Ltd. Sponsored ADR Trade Ideas — SWB:HHB0 - TradingView
Diluted earnings per share (diluted EPS) of XTL Biopharmaceuticals Ltd. Sponsored ADR – LS:A41X7J - TradingView
XTL Biopharmaceuticals Ltd. Sponsored ADR Cash Flow – LSX:A41X7J - TradingView
Average basic shares outstanding of XTL Biopharmaceuticals Ltd. Sponsored ADR – LSX:A41X7J - TradingView
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):